
Wegovy
Productby Novo Nordisk
Heard in 72 episodes across 45 shows since Dec 2025
Wegovy is a brand name for semaglutide, an anti-obesity medication developed by Novo Nordisk for chronic weight management. Administered as a weekly subcutaneous injection, it acts as a GLP-1 receptor agonist to regulate appetite and food intake.
Episodes
This week
Expert statements
Share of the conversation
Mentions of Wegovy per 1,000 mentions of anything, 7-day rolling, across the podcasts PodLume Trends follows.
Show the data
| Day | Share (7-day) | Mentions |
|---|---|---|
| Sep 21 | 0.02‰ | 1 |
| Sep 22 | 0.02‰ | 1 |
| Sep 25 | 0.03‰ | 1 |
| Sep 28 | 0.03‰ | 1 |
| Oct 1 | 0.03‰ | 1 |
| Oct 3 | 0.03‰ | 1 |
| Oct 6 | 0.03‰ | 1 |
| Oct 8 | 0.03‰ | 1 |
| Oct 10 | 0.03‰ | 1 |
| Oct 11 | 0.03‰ | 1 |
| Oct 12 | 0.04‰ | 1 |
| Oct 16 | 0.04‰ | 2 |
| Oct 20 | 0.06‰ | 5 |
| Oct 21 | 0.07‰ | 1 |
| Oct 22 | 0.08‰ | 2 |
| Oct 23 | 0.11‰ | 5 |
| Oct 27 | 0.07‰ | 1 |
| Oct 28 | 0.08‰ | 2 |
| Oct 29 | 0.08‰ | 1 |
| Nov 1 | 0.05‰ | 2 |
| Nov 2 | 0.06‰ | 1 |
| Nov 4 | 0.04‰ | 1 |
| Nov 5 | 0.04‰ | 1 |
| Nov 8 | 0.03‰ | 1 |
| Nov 10 | 0.03‰ | 1 |
| Nov 15 | 0.02‰ | 1 |
| Nov 16 | 0.02‰ | 1 |
| Nov 17 | 0.03‰ | 2 |
| Nov 18 | 0.04‰ | 1 |
| Nov 19 | 0.05‰ | 1 |
Email alert
Email me when Wegovy comes up on a podcast
One email a week at most, with the new episodes that mention Wegovy. Free, no account needed, unsubscribe in one click.
What experts have said about Wegovy
7 statements · 6 positive · 1 negative
Children may become Wegovy’s next growth market.
“Wagovi's next frontier for growth may be children.”
Open the episode · NVIDIA's China Loophole & The Aviation Blame GameListen at 17:31
Pediatric Wegovy expansion could help Novo compete with Eli Lilly.
“expanding to younger children could help Novo fend off its key rival, Eli Lilly.”
Open the episode · NVIDIA's China Loophole & The Aviation Blame GameListen at 17:50
Novo Nordisk’s high-dose Wegovy has efficacy comparable to Eli Lilly’s product
“We have something called the Vigovi HD, Vigovi high dose in the market with efficacy on par with our competitor.”
Open the episode · Mad Money w/ Jim Cramer 8/12/26Listen at 16:01
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Episodes
72 episodes featuring Wegovy, newest first
- Nov 19, 2026
Trump’s summit, AI’s IPO and the politics of pediatric obesityThe HeadlinesNov 19, 2026 - Nov 18, 2026
Gold falters as Anthropic tests IPO appetiteEquity Mates Investing PodcastNov 18, 2026 - Nov 17, 2026
FAA probes network failure as AI markets resetWSJ What’s NewsNov 17, 2026 - Nov 17, 2026
America’s colleges, chips and culture face a trust testMorning Brew DailyNov 17, 2026 - Nov 16, 2026
Washington targets NVIDIA’s overseas China chip accessBrew MarketsNov 16, 2026 - Nov 15, 2026
Biotech investors weigh gene editing, MASH data and RAS riskBreaking BiotechNov 15, 2026